Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Creative Biolabs offers a wide range of products and services related to CD70 CAR-T cells, catering to various needs and requirements. We also provide comprehensive customization services. Our team of experts works closely with clients to develop personalized CD70 CAR-T cell products tailored to their specific research or treatment goals. Contact us and let us help you in your journey towards groundbreaking discoveries in the research of CD70 CAR-T cells.
CD70, also known as cluster of differentiation 70, serves as a ligand for CD27, a TNFR (tumor necrosis factor receptor) superfamily type I transmembrane glycoprotein. CD70 specifically binds to CD27, which is expressed by activated T and B lymphocytes as well as mature dendritic cells. CD70 is a promising target for antibody-based therapies.
Fig.1 Expression of CD70 on human tumor tissues.1
Our CD70 CAR-T cell expression test services include a comprehensive analysis of CD70 expression levels on T cells using cutting-edge technology and state-of-the-art equipment. In addition to our CD70 CAR-T cell expression test services, we offer comprehensive reporting and interpretation of the test results. Based on the findings, our team will offer an in-depth analysis service.
Fig.2 CTX130 potency initially correlates with CD70 expression.2
CD70 CAR-T Cytokine Release Test
Fig.3 ELISA results showed the IFN-γ and IL-2 secretion levels by CD70 CAR.1
CD70 CAR-T In Vitro Cytotoxicity Assay
Cytokine release assays are rapid and straightforward techniques for assessing the activation of T-cells when stimulated by target cells presenting the candidate peptide. We have accumulated significant expertise in cytokine release assays, and we believe it will accelerate our clients' research progress.
Fig.4 The enhanced tumor-killing ability of CD70 CAR-T cells against target cells.1
CD70 CAR-T Cell Proliferation Test
Creative Biolabs provides proliferation tests to accurately evaluate the proliferation capacity of CAR-T cells in response to tumor challenges.
Fig.5 The proliferation of CD70-CAR-T cells measured using CFSE assay.3
CD70 CAR-T Cell Therapy Animal Models
Our team has dedicated significant efforts to enhance the CD70 CAR-T Cell Therapy animal models. Firstly, we have developed more sophisticated and accurate models that better mimic human physiological and immune responses. These models incorporate humanized components, such as human immune cells or tissues, enabling us to better study the interactions between CAR-T cells and the human immune system.
Fig.6 The treatment scheme of CAR-T cells T cells and in vivo optical imaging.1
We have implemented cutting-edge techniques and rigorous protocols to evaluate the efficacy of CAR-T in vivo.
Fig.7 Antitumor response of TanCAR-T cells in human subcutaneous xenograft models.1
Toxicity Evaluation of CD70 CAR-T
Creative Biolabs has been dedicated to enhancing the evaluation methods for CAR-T cell toxicity, focusing on various aspects. Firstly, we have developed sophisticated in vitro models that mimic the tumor microenvironment to better predict the potential toxic effects of CAR-T cells. These models incorporate factors such as immune cells, tumor cells, and cytokines, creating a complex and realistic environment for toxicity assessment.
Fig.8 Evaluation of hematologic toxicity of CD70-CAR-T cells in vivo.3
References
Loading...
| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
| XS-0822-YF8680 | TS-Fluc Anti-Human CD70 scFv (XW-213) CD28-CD3ζ CAR, pCDCAR1 | Human | XW-213 | Mouse | 7H-YB-Fluc-EF1a-scFv-CD28-CD3ζ | Lentiviral vector | |||
| XS-0822-YF8681 | TS-Fluc Anti-Human CD70 scFv (XW-214) CD28-CD3ζ CAR, pCDCAR1 | Human | XW-214 | Mouse | 7H-YB-Fluc-EF1a-scFv-CD28-CD3ζ | Lentiviral vector | |||
| XS-0822-YF8682 | TS-Fluc Anti-Human CD70 scFv (XW-215) CD28-CD3ζ CAR, pCDCAR1 | Human | XW-215 | Mouse | 7H-YB-Fluc-EF1a-scFv-CD28-CD3ζ | Lentiviral vector | |||
| XS-0822-YF9081 | TS-Fluc Anti-Human CD70 scFv (XW-205) 41BB-CD3ζ CAR, pCDCAR1 | Human | XW-205 | Mouse | 7H-YB-Fluc-EF1a-scFv-41BB-CD3ζ | Lentiviral vector | |||
| XS-0822-YF9082 | TS-Fluc Anti-Human CD70 scFv (XW-206) 41BB-CD3ζ CAR, pCDCAR1 | Human | XW-206 | Human | 7H-YB-Fluc-EF1a-scFv-41BB-CD3ζ | Lentiviral vector | |||
| XS-0822-YF9083 | TS-Fluc Anti-Human CD70 scFv (XW-207) 41BB-CD3ζ CAR, pCDCAR1 | Human | XW-207 | Human | 7H-YB-Fluc-EF1a-scFv-41BB-CD3ζ | Lentiviral vector | |||
| XS-0822-YF9084 | TS-Fluc Anti-Human CD70 scFv (XW-208) 41BB-CD3ζ CAR, pCDCAR1 | Human | XW-208 | Human | 7H-YB-Fluc-EF1a-scFv-41BB-CD3ζ | Lentiviral vector | |||
| XS-0822-YF9085 | TS-Fluc Anti-Mouse CD70 scFv (XW-209) 41BB-CD3ζ CAR, pCDCAR1 | Mouse | XW-209 | Mouse | 7H-YB-Fluc-EF1a-scFv-41BB-CD3ζ | Lentiviral vector | |||
| XS-0822-YF9086 | TS-Fluc Anti-Mouse CD70 scFv (XW-210) 41BB-CD3ζ CAR, pCDCAR1 | Mouse | XW-210 | Mouse | 7H-YB-Fluc-EF1a-scFv-41BB-CD3ζ | Lentiviral vector | |||
| XS-0822-YF9087 | TS-Fluc Anti-Mouse CD70 scFv (XW-211) 41BB-CD3ζ CAR, pCDCAR1 | Mouse | XW-211 | Rat | 7H-YB-Fluc-EF1a-scFv-41BB-CD3ζ | Lentiviral vector | |||
| XS-0822-YF9088 | TS-Fluc Anti-Mouse CD70 scFv (XW-212) 41BB-CD3ζ CAR, pCDCAR1 | Mouse | XW-212 | Rat | 7H-YB-Fluc-EF1a-scFv-41BB-CD3ζ | Lentiviral vector | |||
| XS-0822-YF9089 | TS-Fluc Anti-Human CD70 scFv (XW-213) 41BB-CD3ζ CAR, pCDCAR1 | Human | XW-213 | Mouse | 7H-YB-Fluc-EF1a-scFv-41BB-CD3ζ | Lentiviral vector | |||
| XS-0822-YF9090 | TS-Fluc Anti-Human CD70 scFv (XW-214) 41BB-CD3ζ CAR, pCDCAR1 | Human | XW-214 | Mouse | 7H-YB-Fluc-EF1a-scFv-41BB-CD3ζ | Lentiviral vector | |||
| XS-0822-YF9490 | TS-Fluc Anti-Human CD70 scFv (XW-205) CD28-41BB-CD3ζ CAR, pCDCAR1 | Human | XW-205 | Mouse | 7H-YB-Fluc-EF1a-scFv-CD28-41BB-CD3ζ | Lentiviral vector | |||
| XS-0822-YF9491 | TS-Fluc Anti-Human CD70 scFv (XW-206) CD28-41BB-CD3ζ CAR, pCDCAR1 | Human | XW-206 | Human | 7H-YB-Fluc-EF1a-scFv-CD28-41BB-CD3ζ | Lentiviral vector | |||
| XS-0822-YF9492 | TS-Fluc Anti-Human CD70 scFv (XW-207) CD28-41BB-CD3ζ CAR, pCDCAR1 | Human | XW-207 | Human | 7H-YB-Fluc-EF1a-scFv-CD28-41BB-CD3ζ | Lentiviral vector | |||
| XS-0822-YF9493 | TS-Fluc Anti-Human CD70 scFv (XW-208) CD28-41BB-CD3ζ CAR, pCDCAR1 | Human | XW-208 | Human | 7H-YB-Fluc-EF1a-scFv-CD28-41BB-CD3ζ | Lentiviral vector | |||
| XS-0822-YF9494 | TS-Fluc Anti-Mouse CD70 scFv (XW-209) CD28-41BB-CD3ζ CAR, pCDCAR1 | Mouse | XW-209 | Mouse | 7H-YB-Fluc-EF1a-scFv-CD28-41BB-CD3ζ | Lentiviral vector | |||
| XS-0822-YF9495 | TS-Fluc Anti-Mouse CD70 scFv (XW-210) CD28-41BB-CD3ζ CAR, pCDCAR1 | Mouse | XW-210 | Mouse | 7H-YB-Fluc-EF1a-scFv-CD28-41BB-CD3ζ | Lentiviral vector | |||
| XS-0822-YF9496 | TS-Fluc Anti-Mouse CD70 scFv (XW-211) CD28-41BB-CD3ζ CAR, pCDCAR1 | Mouse | XW-211 | Rat | 7H-YB-Fluc-EF1a-scFv-CD28-41BB-CD3ζ | Lentiviral vector | |||
| XS-0823-LX23 | Anti-hCD70 (69A7) ICD(CD28-OX40-CD3ζ) CAR-MA, pAd5f35 Vector | Human | 69A7 | Adenoviral vectors |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
